PLSE Overview

Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. It is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. It is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.

Wall Street analysts forecast PLSE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PLSE is22.00 USD with a low forecast of 22.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Pulse Biosciences Inc revenue for the last quarter amounts to 264.00K USD, decreased

Pulse Biosciences Inc. EPS for the last quarter amounts to -0.26 USD, decreased -16.13

Pulse Biosciences Inc (PLSE) has 116 emplpoyees as of March 20 2026.

Today PLSE has the market capitalization of 1.52B USD.